Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-28T00:15:13.440Z Has data issue: false hasContentIssue false
  • English
  • Français

Influence of Tricalcium Aluminate Phase on In Vitro Biocompatibility and Bioactivity of Calcium Aluminate Bone Cement

Published online by Cambridge University Press:  03 March 2011

S.H. Oh ,
R. Finones ,
S. Jin ,
S.Y. Choi  and
K.N. Kim
S.H. Oh
Affiliation:
Materials Sciences and Engineering Program, Department of Mechanical Aerospace Engineering, University of California at San Diego, La Jolla, California, 92093
R. Finones
Affiliation:
Materials Sciences and Engineering Program, Department of Mechanical Aerospace Engineering, University of California at San Diego, La Jolla, California, 92093
S. Jin*
Affiliation:
Materials Sciences and Engineering Program, Department of Mechanical Aerospace Engineering, University of California at San Diego, La Jolla, California, 92093
S.Y. Choi
Affiliation:
Department of Ceramic Engineering, Yonsei University, Seoul 120-749, Korea
K.N. Kim
Affiliation:
Department of Biomaterials and Bioengineering, Yonsei University, Seoul 120-752, Korea
*
a)Address all correspondence to this author. e-mail: [email protected].This author was an editor of this journal during the review and decision stage. For the JMR policy on review and publication of manuscripts authored by editors, please refer to http://www.mrs.org/publications/jmr/policy.html.
Get access

Abstract

The influence of tricalcium aluminate (3CaO·Al2O3) phase doping on in vitro biocompatibility and bioactivity of calcium aluminate (CaO·Al2O3) based bone cement has been investigated. It is demonstrated that the presence of approximately 25% tricalcium aluminate in the bone cement remarkably improves the bioactivity, yet still retains desirable mechanical strength and biocompatibility. An intermediary compound layer such as Ca3Al2(OH)12 was formed on the surface of the doped sample onto which hydroxyapatite (HAp) began to form soon, after only 2 days of immersion in a simulated body fluid solution. This is about seven-fold acceleration in the HAp formation over undoped calcium aluminate cement on which it took approximately15 days to nucleate the HAp phase. The depth of the HAp-containing layer after60 days of soaking was as much as 85 μm, about an order of magnitude more than the undoped calcium aluminate cement. The dramatically accelerated nucleation and growth of hydroxyapatite caused by the presence of tricalcium aluminate is attributed to the occurrence of intermediate layer materials such as Ca3Al2(OH)12, which most likely acts as the nuclei for HAp formation. This doped bone cement can be useful for injectable orthopedic applications, as the setting time for hardening has also been significantly reduced (by a factor of at least 4) to a practical regime of tens of minutes.

Keywords

Bone cementBiocompatibilityBioactivity
Type
Articles
Information
Journal of Materials Research , Volume 19 , Issue 4 , April 2004 , pp. 1062 - 1067
Copyright
Copyright © Materials Research Society 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1Kokubo, T., Kushitani, H., Ohtsuki, C., Sakka, S. and Yamamuro, T.: J. Mater. Sci. Mater. Med. 4, 1 (1993).CrossRefGoogle Scholar
2Hwang, J.J.H., Siew, C., Robinson, P., Gruninger, S.E., Chow, L.C. and Brown, W.E.: J. Dent. Res. 65, 195 (1986).Google Scholar
3Friedman, C.D., Costantino, P.D., Snyderman, C.H., Chow, L.C. and Takagi, S.: Arch. Facial Plast. Surg. 2, 124 (2000).Google Scholar
4Hench, L.L.: Am. Ceramic. Soc. Bull. 72, 93 (1993).Google Scholar
5Klawitter, J.J. and Hulbert, S.F.: J. Biomed. Mater. Res. Sym. 2, 161 (1971).Google Scholar
6Hentrich, R.L., Graves, G.A., Stein, H.G. and Bajpai, P.K.: J. Biomed. Mater. Res. 5, 25 (1971).CrossRefGoogle Scholar
7Kalite, S.J., Bose, S. and Bandyopadhyay, A.: J. Mater. Res. 17, 3042 (2002).Google Scholar
8Oh, S.H., Choi, S.Y., Lee, Y.K., and Kim, K.N.: (Unpublished work).Google Scholar
9Li, J.W., Leong, J.C.Y., Lu, W.W., Luk, K.D.K., Cheung, K.M.C., Chiu, K.Y. and Chow, S.P.: J. Biomed. Mater. Res. 52, 164 (2000).3.0.CO;2-R>CrossRefGoogle Scholar
10Anderson, J.M. in Biocompatibility Assessment of Medical Devices and Materials , 1st ed., edited by Braybrook, J.H., (John Wiley & Sons, New York, 1997), pp. 140–142Google Scholar
11Kokubo, T., Kushitani, H., Sakka, S., Kitsugi, T. and Yamamuro, T.: J. Biomed. Mater. Res. 24, 721 (1990).Google Scholar
12Oh, S.H., Choi, S.Y., Lee, Y.K. and Kim, K.N.: J. Biomed. Mater. Res. 62, 593 (2002).Google Scholar
13Taylor, H.F.W.: Cement Chemistry , 1st ed. (Academic Press, London, U.K., 1990), pp. 316–344Google Scholar
14Siriphannon, P., Kameshima, Y., Yasumori, A., Okada, K. and Hayashi, S.: J. Biomed. Mater. Res. 52, 30 (2000).3.0.CO;2-Z>CrossRefGoogle Scholar
15Oh, S.H., Choi, S.Y., Lee, Y.K. and Kim, K.N.: J. Biomed. Mater. Res. 67A, 104 (2003).CrossRefGoogle Scholar
16Cho, S.B., Nakanishi, K., Kokubo, T., Soga, N., Ohtsuki, C., Nakamura, T., Kitsugi, T. and Yamamuro, T.: J. Am. Ceram. Soc. 78, 1769 (1995).Google Scholar
17Takadama, H., Kim, H.M., Kokubo, T. and Nakamura, T.: J. Biomed. Mater. Res. 55, 185 (2001).Google Scholar
18Miyazaki, T., Kim, H.M., Miyaji, F., Kokubo, T., Kato, H. and Nakamura, T.: J. Biomed. Mater. Res. 50, 35 (2000).3.0.CO;2-8>CrossRefGoogle Scholar